Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: Anti- insulin antibody levels were similar in the two groups. Insulin lispro was not detectable in the cord blood. During a meal test, areas under the curve for glucose, insulin, and C-peptide were significantly lower in the lispro group. Mean fasting and postprandial glucose concentrations and end point HbA1c were similar in the two groups. The lispro group demonstrated fewer hypoglycemic episodes (symptoms and blood glucose concentrations <55 mg/dl). No fetal or neonatal abnormalities were noted in either treatment group. CONCLUSIONS:
|
Authors | L Jovanovic, S Ilic, D J Pettitt, K Hugo, M Gutierrez, R R Bowsher, E J Bastyr 3rd |
Journal | Diabetes care
(Diabetes Care)
Vol. 22
Issue 9
Pg. 1422-7
(Sep 1999)
ISSN: 0149-5992 [Print] United States |
PMID | 10480503
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hypoglycemic Agents
- Insulin
- Insulin Lispro
|
Topics |
- Adult
- Antibody Formation
- Blood Glucose Self-Monitoring
- Cross Reactions
- Diabetes, Gestational
(drug therapy, immunology, metabolism)
- Female
- Humans
- Hypoglycemic Agents
(adverse effects, blood, therapeutic use)
- Insulin
(adverse effects, analogs & derivatives, blood, therapeutic use)
- Insulin Lispro
- Pregnancy
|